Carmell Therapeutics Announces CEO Transition and New Leadership Incentives
Company Announcements

Carmell Therapeutics Announces CEO Transition and New Leadership Incentives

An update from Carmell Therapeutics (CTCX) is now available.

Carmell Corporation has announced a major leadership change with Rajiv S. Shukla stepping down as CEO, to be succeeded by Kendra Bracken-Ferguson, effective July 30, 2024. Bracken-Ferguson, a seasoned professional in the digital media and beauty industries, will bring her extensive experience from founding BrainTrust and developing over 200 influencer-driven brands to her new role. Alongside a base salary of $300,000, her compensation includes performance-based bonuses and equity awards, with additional severance benefits outlined in her executive employment agreement.

See more data about CTCX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCarmell Therapeutics launches skincare partnership with Ladies Playbook
TheFlyCarmell Therapeutics appoints Bracken-Ferguson as CEO
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App